GLP-1 drugs cut heart and kidney risks in type 1 diabetes study
GLP-1s: A Recent Chapter in Type 1 Diabetes Management? A groundbreaking analysis suggests glucagon-like peptide-1 receptor agonists (GLP-1RAs) – already well-established in type 2 diabetes treatment – could offer significant benefits for individuals living with type 1 diabetes (T1D). The research, published in Nature Medicine, points to reduced risks of cardiovascular events and kidney disease … Read more